Abstract 3203
Background
REACHIN trial met its primary endpoint of improving PFS in patients with biliary tract cancer (BTC) treated with regorafenib (R) as compared to placebo (P): Median (m) PFS for R was 3.0 months (mo) and 1.5 mo for P (HR = 0.49; 95% CI: 0.29-0.81, p = 0.005)1. We exploratory analyzed the benefit of R according to tumor location (TL): intra-hepatic (ICC), extra-hepatic (ECC), gallbladder (GB) or peri-hilar (PH). The early metabolic response (EMR) by treatment was evaluated by FDG PET/CT.
Methods
TL were recorded at randomization of 66 patients in REACHIN (NCT02162914). We analyzed mPFS (95%CI) according to TL. EMR was evaluated comparing FDG tumor metabolism at baseline and after 2 weeks of treatment in the 2 arms if there was at least one FDG positive lesion at baseline, with a Tumour/Liver-uptake-ratio ≥1.4 (MIMvista software).
Results
Table:
743P
R | R | R | P | P | P | |
---|---|---|---|---|---|---|
N | mPFS (mo) | 95%CI | N | mPFS (mo) | 95%CI | |
ICC | 23 | 3.0 | 1.5–4.9 | 19 | 1.5 | 1.1–2.1 |
ECC | 3 | 1.4 | 0.5-5.3 | 6 | 1.5 | 0.6–4.7 |
GB | 4 | 4.7 | 0.0-8.8 | 5 | 1.6 | 0.4-2 |
PH | 3 | 2.6 | 1.1-4.5 | 3 | 0.5 | 0.0-3.0 |
mPFS data are summarized in the table For PET study (29 patients, P n = 15/R n = 14), both ΔSUVmax, ΔMTV and ΔTLG (%change from baseline) show a significant decrease between baseline and FU scan in R (P = 0.0151*;0.037**; 0.0056**) as compared to P. Main tumour SUVmax was significantly decreased in R but not in P(P = 0.0353* vs 0.5614). Both TLG and MTV significantly increased in the P (p = 0.0004***; 0.0002***; ) while a stabilization was observed for R (P = 0.3910; 0.2412). There was no relevant treatment’s related impact on the reference-liver-uptake (P = 0.381(P); 0.6149(R)).
Conclusions
ICC location was predominant (64%). mPFS in P arm is similar according to TL. Despite exploratory value and small number of patients per tumor location, R seems superior to P in ICC, GB and PH. Despite limited number of patients, FDG PET/CT seems performant to discriminate EMR in patients treated with R as compared to P. Additional analysis are ongoing to estimate if these EMR also correlate with PFS and OS.
Clinical trial identification
NCT02162914.
Editorial acknowledgement
CUB Hôpital Erasme (Brussels, Belgium). Support from Bayer HealthCare. REACHIN is a BDGO cooperative study.
Legal entity responsible for the study
CUB Hôpital ERASME, Brussels, Belgium.
Funding
Bayer Healthcare.
Disclosure
A. Demols: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self): Bayer Healthcare. All other authors have declared no conflicts of interest. All other authors have declared no conflicts of interest.
Resources from the same session
1058 - Assessment of CPS+EG, Neo-Bioscore and modified Neo-Bioscore in breast cancer patients treated with preoperative systemic therapy: a multicenter cohort study
Presenter: LING XU
Session: Poster Display session 2
Resources:
Abstract
1156 - The concordance of treatment decision guided by Oncotype and the PREDICT tool in early stage breast cancer
Presenter: Hadar Goldvaser
Session: Poster Display session 2
Resources:
Abstract
3447 - Influence of first treatment delay on survival among breast cancer subtypes
Presenter: Irene Zarcos Pedrinaci
Session: Poster Display session 2
Resources:
Abstract
3505 - Clinical features of early-stage (I-III) triple-negative breast cancer (TNBC) patients with tumors exhibiting low-overall change in molecular profile after neoadjuvant therapy.
Presenter: Nour Abuhadra
Session: Poster Display session 2
Resources:
Abstract
5442 - Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective
Presenter: Marcos Magalhaes
Session: Poster Display session 2
Resources:
Abstract
1570 - Anti-mullerian hormone (AMH) levels and antral follicle counts (AFC) may predict ovarian reserves before systemic chemotherapy (SC) in women with breast cancer(BC); a prospective clinical study
Presenter: Cetin Ordu
Session: Poster Display session 2
Resources:
Abstract
2698 - Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.
Presenter: Giuseppe Cancello
Session: Poster Display session 2
Resources:
Abstract
3104 - Novel Blood Based Circulating Tumor Cell Biomarker For Breast Cancer Detection
Presenter: Chun-Yu Liu
Session: Poster Display session 2
Resources:
Abstract
4631 - Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response of ER-Positive HER2-Negative Breast Cancer Patients to Neo-Adjuvant Chemotherapy
Presenter: Claudia Mazo
Session: Poster Display session 2
Resources:
Abstract
4632 - Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Presenter: Andri Papakonstantinou
Session: Poster Display session 2
Resources:
Abstract